血清肿瘤标志物预测晚期非小细胞肺癌靶向治疗疗效的临床价值

Serum tumor markers to predict advanced non-small cell lung cancer targeted therapy efficacy of clinical value

目的观察研究血清肿瘤标志物对于预测晚期非小细胞肺癌靶向治疗疗效的临床价值。方法选择本院收入的晚期非小细胞肺癌患者100例,对其进行靶向治疗,观察患者治疗前后血清肿瘤标志物的变化以及其与近期疗效的关联。结果有效患者治疗后的血清CEA、CA125、NSE水平均显著低于治疗前(P<0.05);PD患者治疗后血清CEA、CA125、Cyfra21-1水平均显著高于治疗前(P<0.05);有效患者治疗前血清CEA、CA125基线水平显著高于SD患者和PD患者,差异具有统计学意义(P<0.05)。结论肿瘤标志物中,血清CEA、CA125、Cyfra21-1NSE水平可在一定程度上对非小细胞肺癌靶向治疗疗效进行判定,且上述指标的水平与治疗效果往往呈反比关系,其下降幅度越大,代表靶向治疗效果越好,且检测方便、操作度高,可为临床治疗效果以及该病的复发提供适当的参考价值。值得临床大力推广。

Objective To observe the serum tumor markers for predicting the late non-small cell lung cancer targeted therapy efficacy of clinical value. Methods Our hospital income, 100 cases of patients with advanced non-small cell lung cancer, targeted therapy, to observe the change of the before and after treatment in patients with serum tumor markers, and its connection with the recent curative effect. Results The effective after treatment in patients with serum CEA, CA125, NSE levels were significantly lower than before treatment(P < 0.05); PD patients after treatment serum CEA, CA125, Cyfra21-1 levels were significantly higher than before treatment(P < 0.05); Effective treatment in patients with previous baseline serum CEA, CA125 levels were significantly higher in patients with SD and PD patients, the difference is statistically significant(P < 0.05). Conclusion Tumor markers in serum CEA, CA125, nse level Cyfra21-1 May to a certain extent to determine non-small cell lung cancer targeted therapy efficacy, and the level of the index and treatment effect is often assumes the inverse relationship, the greater its decline, on behalf of the targeted therapy effect is better, and convenient detection, high degree of operation, for the clinical treatment effect and the relapse of the disease to provide the appropriate reference value.Is worth promoting in the clinical practice.